57th ASH Annual Meeting and Exposition (December 5-8, 2015): 703. Adoptive Immunotherapy: Poster III

Adoptive Immunotherapy Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

Targeting Aurora Kinase with a Superior T-Cell Receptor Gene-Transfer Vector

Nicholas Casey, PhD¹^*, Hiroshi Fujiwara, MD, PhD¹, Kazushi Tanimoto, MD, PhD¹^*, Sachiko Okamoto, PhD²^*, Junichi Mineno, PhD³^*, Kiyotaka Kuzushima, MD, PhD⁴^*, Hiroshi Shiku, MD, PhD⁵^* and Masaki Yasukawa, MD, PhD¹

¹Department of Hematology, Clinical Immunology and Infectious disease, Ehime University Graduate School of Medicine, Toon, Japan
²CDM Center, Takara Bio Inc., Otsu, Japan
³Takara Bio Inc., Otsu, Japan
⁴Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan
⁵Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan

4292

Immunotherapy with Chimeric Antigen Receptor Targeting Intracellular WT1 Gene Product Complexed with HLA-a*24:02 Molecule

Hiroaki Ikeda, MD, PhD¹^*, Yasushi Akahori, PhD¹^*, Motohiro Yoneyama¹^*, Yuki Orito¹^*, Yoshihiro Miyahara¹^*, Yasunori Amaishi²^*, Sachiko Okamoto²^*, Junichi Mineno, PhD²^*, Kazutoh Takesako, PhD²^*, Hiroshi Fujiwara, MD, PhD³, Masaki Yasukawa, MD, PhD³ and Hiroshi Shiku, MD, PhD¹^*

¹Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan
²Takara Bio Inc., Otsu, Japan
³Department of Hematology, Clinical Immunology and Infectious disease, Ehime University Graduate School of Medicine, Toon, Japan

4293

An Optimized, Large Scale Generation and Validation of Aspergillus-Specific T Lymphocytes for the Management of Invasive Aspergillosis in Immunocompromised Patients

Anastasia Papadopoulou, PhD^1,2^*, Panayotis Kaloyannidis, MD³^*, Maria Alvanou^1,4^*, Joanne Kalogeropoulou⁵^*, Achilles Anagnostopoulos⁶ and Evangelia Yannaki, MD¹

¹Hematology-BMT Unit, Gene and Cell Therapy Center, George Papanicolaou Hospital, Thessaloniki, Greece
²Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
³Adult Hematology &Stem cell Transplant, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia
⁴School of Biology, Department of Genetics, Development and Molecular Biology, Aristotle University, Thessaloniki, Greece
⁵Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
⁶Hematology-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece

4294

Adoptive T Cell Therapy for Polyomaviral Infections and Related Diseases

Dhana Chinnasamy, PhD¹^*, Greg Whitehill, BS¹^*, Keyvan Keyvanfar, BS¹^*, Isaac Brownell, MD, PhD²^*, Christopher Buck, PhD³^*, Pawel Muranski, MD¹ and Austin John Barrett, MD, FRCP, FRCPath¹

¹Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
²Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
³Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

4295

Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells

Aaron Foster, PhD^*, Aruna Mahendravada^*, Nicholas P Shinners, PhD^*, Peter Chang, PhD^*, An Lu^*, Eva Morschl, PhD^*, Joanne Shaw, PhD^*, Sunandan Saha, PhD^*, Kevin M Slawin, MD^* and David M Spencer, PhD^*

Bellicum Pharmaceuticals, Houston, TX

4296

ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment

Mattias Carlsten, M.D., Ph.D.¹^*, Ali Namazi, MD²^*, Robert N. Reger, B.S.¹^*, Maria Berg²^* and Richard W. Childs, M.D.¹

¹National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
²National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD

4297

NK-92 Therapy Is Well Tolerated, Has Minimal Toxicity and Shows Efficacy in a Phase I Trial of Patients with Relapsed/Refractory Hematological Malignancies Relapsing after Autologous Stem Cell Transplantation

Brent Williams, MD, PhD¹^*, Bertrand Routy, MD¹, Neal denHollander, PhD²^*, Xing-Hua Wang, MD¹^*, Amelie Chaboureau, MSc¹^*, Sowmya Viswanathan, PhD¹^* and Armand Keating, MD¹

¹Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada
²Department of Laboratory Medicine, University Health Network, Toronto, ON, Canada

4298

Adoptively Transferred CMV-Specific T-Cells Responsive to Immunodominant CMVpp65 Epitopes Extend Durable in-Vivo Suppression of Clonogenic CMVpp65 [+] Human Colon Carcinoma Cells in Comparison to T-Cells Responsive to Subdominant Epitopes

Aisha N Hasan, MD^1,2^*, Annamalai Selvakumar, PhD³^*, Tzu-Yun Kuo^3,4^* and Richard J O'Reilly, MD^1,2

¹Weill Cornell Medical College, New York, NY
²Pediatric Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY
⁴Weill Cornell Graduate School of Medical Sciences, New York, NY

4299

BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)

Barbarella Lucarelli, MD¹^*, Pietro Merli, MD¹^*, Alice Bertaina, MD, PhD², Matilde Sinibaldi, PhD¹^*, Stefania Gaspari, MD¹^*, Luisa Strocchio, MD¹^*, Angela Pitisci, PhD¹^*, Giuseppina Li Pira, PhD¹^*, Giuseppe Maria Milano, MD¹^*, Annemarie Moseley, MD, PhD³^*, Concetta Quintarelli, PhD²^* and Franco Locatelli, Prof, MD, PhD⁴^*

¹Ospedale Pediatrico Bambino Gesù, Rome, Italy
²Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
³Bellicum Pharmaceuticals, Houston, TX
⁴Oncoematologia Pediatrica, Ospedale Pediatrico Bambino Gesù, Rome, Italy

4300

Cancer Germline Antigen Specific CTL As Immunotherapy for Neuroblastoma

Dan Li, MD^1,2^*, Fanqi Bai, MD¹^*, Kumaran Sundaram, PhD¹^*, Deepa K. Krishnadas, PhD¹^* and Kenneth Lucas, MD¹

¹Pediatric Hematology/Oncology, University of Louisville, Louisville, KY
²Cancer Center, The First Hospital of Jilin University, Changchun, China

See more of: Adoptive Immunotherapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH